XML 72 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 29, 2018
Dec. 17, 2018
Jul. 30, 2013
Dec. 31, 2018
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2018
Dec. 31, 2015
U.S./RoW [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Expected upfront, non-contingent and time-based payments     $ 374.0          
Development and regulatory approval milestones     550.0          
Commercial sales milestone     325.0          
Shared development costs               $ 233.0
Additional consideration based on net sales description             Low 20% range  
U.S./RoW [Member] | FibroGen, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Shared development costs               $ 116.5
China [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Development and regulatory approval milestones     161.0          
Commercial sales milestone     167.5          
Proceeds from upfront payments     28.2          
Contingent payment     $ 20.0          
Estimated joint development service period           2018    
Estimated joint development extended service period           2020 2024  
Milestone payment, revenue recognition $ 6.0 $ 6.0   $ 9.9 $ 15.0   $ 12.0